Markets:

Overview

News

Currencies

International

Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

9.710 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher ↗

July 31, 2024

Via Benzinga

Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings ↗

July 31, 2024

Via Benzinga

Topics Stocks

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program ↗

July 31, 2024

FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival.

Via Benzinga

Ground Cinnamon Recalls: What to Know as FDA Issues Alert Over Lead Levels ↗

July 31, 2024

New ground cinnamon recalls are in effect as the FDA warns consumers about increased lead levels in some of these products.

Via InvestorPlace

Topics Product Recall

Why Are Chip Stocks Up Today? ↗

July 31, 2024

Chip stocks are up today and investors wondering why will find all of the news explaining the rally in the sector on Wednesday.

Via InvestorPlace

FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts ↗

July 31, 2024

FibroGen layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials.

Via InvestorPlace

Topics Workforce

Why is Macrogenics (MGNX) Stock Down 28% Today? ↗

July 31, 2024

Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial.

Via InvestorPlace

Why Is FibroGen (FGEN) Stock Down 44% Today? ↗

July 31, 2024

FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 31, 2024

It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning!

Via InvestorPlace

Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

July 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 04, 2024

Via Benzinga

What's Going On With FibroGen Stock Tuesday? ↗

June 04, 2024

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 04, 2024

It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!

Via InvestorPlace

Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

June 04, 2024

Via Benzinga

FibroGen Stock Is Surging After The Bell: What's Going On? ↗

June 03, 2024

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 03, 2024

Via Benzinga

7 Penny Biotech Stocks to Triple Your Investment ↗

May 28, 2024

Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.

Via InvestorPlace

Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS

May 08, 2024

Via AB Newswire

FibroGen Shares Climb On Strong Q1 Sales ↗

May 07, 2024

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902...

Via Benzinga

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 07, 2024

Via Benzinga

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗

May 07, 2024

Via Benzinga

Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

May 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 07, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

May 07, 2024

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday!

Via InvestorPlace

FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 ↗

May 06, 2024

FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 06, 2024

Via Benzinga

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 03, 2024

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 03, 2024

Via Benzinga

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape ↗

April 03, 2024

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements...

Via Benzinga

3 Nightmare Nasdaq Stocks Not Worth Holding Another Day ↗

March 20, 2024

Selling these three NASDAQ stocks might be the best option now, as they continue to show potential issues and continued weakness.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.